Ledger. Australian venture funding, tracked

THRUST Strategic Communications

Monique Allaire

Coverage

Stories naming Monique Allaire. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Key hire

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.

Brandon BioCatalyst portfolio 12 May 2022 AmylinBiosplice TherapeuticsElcelyx TherapeuticsGlyscendJohns Hopkins UniversityTHRUST Strategic CommunicationsAshish NimgaonkarMark FinemanMonique Allaire
Key hire

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.

Brandon Capital portfolio 12 May 2022 AmylinBiosplice TherapeuticsElcelyx TherapeuticsGlyscendJohns Hopkins UniversityTHRUST Strategic CommunicationsAshish Nimgaonkar, M.D.Mark Fineman, Ph.D.Monique Allaire

Something wrong? Tell us